Icosavax, Inc. financial data

Symbol
ICVX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1930 Boren Ave., Suite 1000, Seattle, Washington
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q3 2023 - Nov 14, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.67 K % -22.3%
Debt-to-equity 8.94 % +45.1%
Return On Equity -43.1 % -25.4%
Return On Assets -39.5 % -22.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.1 M shares +25.5%
Common Stock, Shares, Outstanding 50.1 M shares +25.9%
Entity Public Float 184 M USD
Common Stock, Value, Issued 7 K USD +40%
Weighted Average Number of Shares Outstanding, Basic 50 M shares +25.9%
Weighted Average Number of Shares Outstanding, Diluted 50 M shares +25.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 70 M USD +10.7%
General and Administrative Expense 35.8 M USD +30.3%
Operating Income (Loss) -106 M USD -20.1%
Nonoperating Income (Expense) 9.17 M USD +406%
Net Income (Loss) Attributable to Parent -96.7 M USD -12%
Earnings Per Share, Basic -2.22 USD/shares +20%
Earnings Per Share, Diluted -2.22 USD/shares +20%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash, Cash Equivalents, and Short-term Investments 229 M USD
Assets, Current 235 M USD +2.88%
Property, Plant and Equipment, Net 11.4 M USD -3.51%
Operating Lease, Right-of-Use Asset 2.98 M USD -10.7%
Other Assets, Noncurrent 1.61 M USD
Assets 251 M USD +3.04%
Accrued Liabilities, Current 9.61 M USD +42.9%
Liabilities, Current 13 M USD -0.02%
Operating Lease, Liability, Noncurrent 5.89 M USD +15.7%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 18.9 M USD +3.85%
Accumulated Other Comprehensive Income (Loss), Net of Tax -48 K USD +92.1%
Retained Earnings (Accumulated Deficit) -259 M USD -59.6%
Stockholders' Equity Attributable to Parent 232 M USD +2.98%
Liabilities and Equity 251 M USD +3.04%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.6 M USD -24%
Net Cash Provided by (Used in) Financing Activities 117 K USD -57.6%
Net Cash Provided by (Used in) Investing Activities 12 M USD
Common Stock, Shares Authorized 500 M shares 0%
Common Stock, Shares, Issued 50.1 M shares +25.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 63.2 M USD -3.55%
Deferred Tax Assets, Valuation Allowance 36.4 M USD +77.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 38.5 M USD +84.9%
Operating Lease, Liability 8.07 M USD +20.8%
Depreciation 643 K USD +1395%
Payments to Acquire Property, Plant, and Equipment 1.57 M USD +40.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -96.2 M USD +1.29%
Property, Plant and Equipment, Gross 12.5 M USD +975%
Operating Lease, Liability, Current 2.19 M USD +37.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.2 M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 365 K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.57 M USD -15.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.27 M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 17.3 M USD +37.1%
Preferred Stock, Shares Authorized 50 M shares
Unrecognized Tax Benefits 1.55 M USD +104%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.34 M USD +3%
Additional Paid in Capital 491 M USD +26.5%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 25.1 M USD +30.5%
Interest Expense 263 K USD